Chipotle's Cultivate Next and Sofinnova back IMIO's farm biologicals

IMIO has raised $12M from Sofinnova and Chipotle's Cultivate Next, a pairing that puts a life-sciences venture investor and the venture arm of a restaurant chain on the same cap table.

The company's stated purpose is tightly scoped: it makes biologicals reliable for farmers. That framing is the whole pitch. Biological inputs — products built on living microorganisms rather than synthetic chemistry — are pitched across agriculture as a way to improve how fields perform, but growers have long treated them with skepticism because field results can vary from one season, soil type or batch to the next. IMIO's positioning is built around dependability rather than novelty.

The investor list is the most revealing detail in the announcement. Cultivate Next is Chipotle's venture vehicle, which gives an agricultural supplier a backer from the food side of the supply chain rather than only the usual agtech and life-sciences pool. Sofinnova brings a venture investor with a deep history in biology-adjacent companies. For a company whose central claim is that its microbes will behave predictably, having both a biology-focused fund and a customer-adjacent food company behind it is a meaningful signal.

The announcement did not disclose the round's structure, the company's valuation, its headcount or its revenue. Nor did it specify what the capital will be used for, or whether investors beyond Sofinnova and Cultivate Next participated. Those omissions leave open the basic questions a grower-facing business eventually has to answer: how far the product has been scaled commercially, and how quickly the company intends to expand.

What is clear is the bet being made. Biologicals have spent years as a promising category with an adoption problem, and IMIO is asking investors to fund the unglamorous half of the problem — not discovery, but consistency.